Payment overview · 2025
General Payments
$4,170.71
168 reported records · 31 companies
Healthcare provider profile · identity verified
Arthur Pinkhasov, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FOREST HILLS, NY · NPI 1588946396
Verified facts
What the public records show
CMS Open Payments records show Arthur Pinkhasov, MD received $4,170.71 in general payments during 2025 across 168 reported records.
Amgen Inc. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Caplyta, Creon, Farxiga, Gemtesa, Ibsrela, Kerendia, Linzess, Mounjaro, Nurtec Odt, Opzelura, Ozempic, Qulipta, Rexulti, Ubrelvy, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 648 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ubrelvy by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ibsrela by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Caplyta by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Opzelura by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $476.30 | 11.4% | 14 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $361.36 | 8.7% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $343.51 | 8.2% | 13 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $331.33 | 7.9% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $287.38 | 6.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $243.62 | 5.8% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $225.09 | 5.4% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $213.93 | 5.1% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $189.79 | 4.5% | 9 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $184.17 | 4.4% | 9 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $123.41 | 3.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $122.69 | 2.9% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $121.96 | 2.9% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.87 | 2.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $93.78 | 2.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $80.25 | 1.9% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $78.28 | 1.9% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $77.29 | 1.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.19 | 1.8% | 4 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $62.02 | 1.5% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $55.98 | 1.3% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $47.05 | 1.1% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $42.15 | 1.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.37 | 1.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $39.69 | 0.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.99 | 0.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.53 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.02 | 0.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.76 | 0.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.99 | 0.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.96 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,170.71 | 168 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $351.30 | 13 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $331.33 | 12 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $287.38 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $261.67 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $226.61 | 11 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $223.87 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $220.70 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $213.93 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $196.62 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $189.79 | 9 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $184.17 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $174.46 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $173.74 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $137.49 | 6 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $123.41 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.69 | 4 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $121.96 | 5 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $120.43 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.87 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $93.78 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.74 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $80.25 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $77.29 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $75.19 | 4 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $62.02 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $55.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.63 | 2 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $47.05 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $39.69 | 2 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $38.45 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.86 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 278 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 45 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 648 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 175 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 165 | exact normalized | Medicare Part D |
| OPZELURA opzelura |
2025 | Opzelura | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 88 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 158 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 159 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
278 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
648 | 80 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
88 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
159 | 19 |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
327 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | OPZELURA open payments reported associated product |
CMS Open Payments — General Payments 59568 supporting records · 12571 recipient NPIs · example record 1225959946 |
Opzelura · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
175 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
158 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
158 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
165 | 27 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
100 | 15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 929 | 119 |
| Linzess | Linaclotide | 648 | 80 |
| Vascepa | Icosapent Ethyl | 459 | 65 |
| Myrbetriq | Mirabegron | 327 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 51 |
| Zenpep | Lipase/Protease/Amylase | 309 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 302 | 58 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 298 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 51 |
| Creon | Lipase/Protease/Amylase | 278 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 41 |
| Jublia | Efinaconazole | 242 | 33 |
| Losartan Potassium | Losartan Potassium | 241 | 42 |
| Restasis | Cyclosporine | 224 | 30 |
| Gabapentin | Gabapentin | 223 | 43 |
| Meclizine Hcl | Meclizine Hcl | 213 | 44 |
| Dexilant | Dexlansoprazole | 189 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 33 |
| Metformin Hcl | Metformin Hcl | 178 | 39 |
| Mounjaro | Tirzepatide | 175 | 29 |
| Finasteride | Finasteride | 167 | 28 |
| Nurtec Odt | Rimegepant Sulfate | 165 | 27 |
| Ubrelvy | Ubrogepant | 159 | 19 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 158 | 24 |
| Rexulti | Brexpiprazole | 158 | 21 |
| Famotidine | Famotidine | 150 | 32 |
| Spiriva Respimat | Tiotropium Bromide | 144 | 18 |
| Lactulose | Lactulose | 143 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 139 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 34 |
| Xiidra | Lifitegrast | 131 | 18 |
| Montelukast Sodium | Montelukast Sodium | 129 | 16 |
| Trazodone Hcl | Trazodone Hcl | 129 | 19 |
| Omeprazole | Omeprazole | 126 | 24 |
| Allopurinol | Allopurinol | 115 | 20 |
| Simvastatin | Simvastatin | 111 | 19 |
| Eliquis | Apixaban | 107 | 13 |
| Lisinopril | Lisinopril | 107 | 19 |
| Furosemide | Furosemide | 104 | 22 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 103 | 18 |
| Diclofenac Potassium | Diclofenac Potassium | 101 | 16 |
| Meloxicam | Meloxicam, Submicronized | 100 | 17 |
| Ztlido | Lidocaine | 100 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 97 | 18 |
| Azelastine Hcl | Azelastine Hcl | 96 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 20 |
| Carvedilol | Carvedilol | 89 | 14 |
| Jardiance | Empagliflozin | 89 | 18 |
| Qulipta | Atogepant | 88 | 11 |
| Tradjenta | Linagliptin | 86 | 14 |
| Metformin Er Gastric | Metformin Hcl | 84 | 14 |
| Ozempic | Semaglutide | 84 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 84 | 17 |
| Sertraline Hcl | Sertraline Hcl | 83 | 14 |
| Meloxicam | Meloxicam | 82 | 22 |
| Trulicity | Dulaglutide | 82 | 12 |
| Ezetimibe | Ezetimibe | 80 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 80 | 12 |
| Repatha Sureclick | Evolocumab | 79 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 14 |
| Donepezil Hcl | Donepezil Hcl | 77 | 17 |
| Januvia | Sitagliptin Phosphate | 76 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 75 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 73 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 12 |
| Alendronate Sodium | Alendronate Sodium | 72 | 17 |
| Opzelura | Ruxolitinib Phosphate | 72 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 69 | 21 |
| Synthroid | Levothyroxine Sodium | 68 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 67 | 16 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 65 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 62 | suppressed |
| Nystatin | Nystatin | 62 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | suppressed |
| Atenolol | Atenolol | 60 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 60 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 11 |
| Lidocaine | Lidocaine | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Potassium Chloride | Potassium Chloride | 53 | 14 |
| Glimepiride | Glimepiride | 52 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 52 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | 11 |
| Trulance | Plecanatide | 50 | suppressed |
| Calcipotriene | Calcipotriene | 49 | suppressed |
| Irbesartan | Irbesartan | 49 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 48 | 11 |
| Gemtesa | Vibegron | 47 | suppressed |
| Torsemide | Torsemide | 46 | suppressed |
| Indapamide | Indapamide | 45 | suppressed |
| Kerendia | Finerenone | 45 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Azithromycin | Azithromycin | 44 | 37 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 11 |
| Valsartan | Valsartan | 44 | suppressed |
| Aplenzin | Bupropion Hbr | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 40 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | 12 |
| Lofena | Diclofenac Potassium | 38 | suppressed |
| Tacrolimus | Tacrolimus | 38 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 37 | suppressed |
| Benicar | Olmesartan Medoxomil | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 30 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Nexium | Esomeprazole Magnesium | 35 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 35 | 28 |
| Cilostazol | Cilostazol | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Bystolic | Nebivolol Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Prednisone | Prednisone | 30 | 23 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Ibsrela | Tenapanor Hcl | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Latuda | Lurasidone Hcl | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 12 |
| Clotrimazole | Clotrimazole | 20 | 13 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Caplyta | Lumateperone Tosylate | 17 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Migranal | Dihydroergotamine Mesylate | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Uloric | Febuxostat | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 14 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Uroxatral | Alfuzosin Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Licart | Diclofenac Epolamine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,170.71 · 168 records | Amgen Inc. | AIRSUPRA, Auvelity, CAPLYTA, CREON, CREXONT, Cologuard Collection Kit, DUPIXENT, ELYXYB - CELECOXIB, FARXIGA, GEMTESA, GVOKE HYPOPEN, IBSRELA, INGREZZA, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KRYSTEXXA, Kerendia, LEQEMBI, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OPZELURA, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, UBRELVY, VRAYLAR, VYEPTI, Veozah, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE, ZTLido | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error